Annotation Detail

Information
Associated Genes
FGFR1
Associated Variants
FGFR1 AMPLIFICATION ( ENST00000425967.8 )
FGFR1 AMPLIFICATION ( ENST00000425967.8 )
Associated Disease
breast cancer
Source Database
CIViC Evidence
Description
Phase 1 study of FGFR-inhibitor BGJ398 in advanced cancer with FGFR-aberrations. Among the 26 patients with breast cancer and FGFR1/2 amplification (n=25, n= 21 with FGFR1 amplification only) or FGFR3 mutation (n=1) four (15.4%) had a reduced tumor burden. In total, 10 of 32 patients with breast cancer treated at doses >100mg had a best response of SD.
Variant Origin
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/1909
Gene URL
https://civic.genome.wustl.edu/links/genes/1885
Variant URL
https://civic.genome.wustl.edu/links/variants/267
Rating
2
Evidence Type
Predictive
Disease
Breast Cancer
Evidence Direction
Does Not Support
Drug
Infigratinib
Evidence Level
B
Clinical Significance
Sensitivity/Response
Pubmed
27870574
Drugs
Drug NameSensitivitySupported
InfigratinibSensitivityfalse